Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.49 |
| ▸ | FABP7 | O15540 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1869833 | 0.87 | FABP5 (0.50) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL119579 | 0.84 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL29397325 | 0.84 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL29649593 | 0.84 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL25179588 | 0.83 | CASP3 (0.47) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL29855327 | 0.83 | CASP3 (0.47) | KMT2AFABP5FABP7EPHX2CASP3 | |
| Water SCHEMBL21056515 | 0.83 | KMT2A (0.47) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL900046 | 0.83 | KMT2A (0.47) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL7640990 | 0.82 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL21950699 | 0.82 | KMT2A (0.46) | KMT2AFABP5FABP7EPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421878-B1 | ANIONIC OLIGOSACCHARIDE CONJUGATES | GLYCAN BIOSCIENCES LLC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-8597632-B2 | Anionic oligosaccharide conjugates | GLYCAN BIOSCIENCES LLC (US) | 2013-12-03 | — | — | US | disclosed |
| US-20110195025-A1 | ANIONIC OLIGOSACCHARIDE CONJUGATES | GLYCAN BIOSCIENCES PTY LTD (AU) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195025-A1 | ANIONIC OLIGOSACCHARIDE CONJUGATES | FUT6, FUT5, CSGALNACT1 | KMT2A 3068/4885FABP5 892/4885FABP7 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.